Press Release Source: Reportlinker on Tuesday August 10, 2010, 10:00 am EDT
NEW YORK, Aug. 10 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:
Antipsychotic Drugs: Technologies and Global Markets
reportlinker.com/p0236244/Antipsychotic-Drugs-Technologies-and-Global-Markets.html
The total worldwide market for antipsychotic drugs is expected to reach $19.6 billion in 2010. with continued market penetration into new diseases and price increases for currently marketed antipsychotics, this market is expected to grow to a high of $20.8 billion in 2011 and then hit a low of $14.4 billion in 2013, before resuming growth again to $14.8 billion in worldwide sales for 2014. this represents a total compound annual growth rate (CAGR) of -4.6%.
Most atypical antipsychotics will lose patent exclusivity through the study period, resulting in a compound annual growth rate (CAGR) of -3.7%. this market will be worth an estimated $18.5 billion by the end of 2010, but decrease to $14.5 billion in 2014.
Antipsychotic drug sales are expected to remain strong in long-acting injectable (depot) formulations. Long-acting injectables are forecast to record a 16.6% compound annual growth rate (CAGR) during this time period, increasing from $1.5 billion in 2009 to $3.2 billion in 2014.
Chapter- 1: INTRODUCTION — Complimentary
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THIS STUDY 2
INFORMATION SOURCES 4
AUTHOR’S CREDENTIALS 4
RELATED BCC WORK CREDENTIALS 4
BCC ONLINE SERVICES 4
SUMMARY TABLE THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, THROUGH 2014 ($, MILLIONS) 7
SUMMARY FIGURE THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, 2010–2014 ($, MILLIONS) 7
DEFINITION OF AN ANTIPSYCHOTIC DRUG 8
HISTORY OF ANTIPSYCHOTIC DRUGS 9
TYPES OF ANTIPSYCHOTICS ON THE MARKET 10
TYPICAL ANTIPSYCHOTICS 10
Typical Antipsychotics (Continued) 11
TABLE 1 CLASSES OF TYPICAL ANTIPSYCHOTICS ON THE MARKET AND THEIR SIDE EFFECTS 12
ATYPICAL ANTIPSYCHOTICS 13
TABLE 2 CURRENTLY APPROVED ATYPICAL ANTIPSYCHOTICS ON THE MARKET 14
TABLE 2 (CONTINUED) 15
TABLE 3 FEATURES OF TYPICAL VERSUS ATYPICAL ANTIPSYCHOTICS 15
TABLE 4 COST OF SELECTED ATYPICAL AND TYPICAL ANTIPSYCHOTIC DRUGS ($) 16
RECEPTOR TARGETS OF ANTIPSYCHOTIC DRUGS 16
SIDE EFFECTS OF ANTIPSYCHOTICS 20
NEUROLOGIC SIDE EFFECTS (EXTRAPYRAMIDAL SYMPTOMS) 21
ANTICHOLINERGIC SIDE EFFECTS 22
CARDIOVASCULAR SIDE EFFECTS 22
METABOLIC SIDE EFFECTS 23
OTHER SIDE EFFECTS 24
TABLE 5 COMPARISON OF SIDE EFFECT PROFILES OF ANTIPSYCHOTICS ON THE MARKET 25
ANTIPSYCHOTICS IN CLINICAL DEVELOPMENT 25
TABLE 6 ANTIPSYCHOTICS IN CLINICAL TRIALS, ORDERED BY PHASE 26
TABLE 6 (CONTINUED) 27
TABLE 7 NUMBER OF ANTIPSYCHOTICS IN CLINICAL TRIALS, BY PHASE (NUMBER/%) 27
FIGURE 1 ANTIPSYCHOTICS IN CLINICAL TRIALS BY PRIMARY RECEPTOR TARGET 28
TABLE 8 COMPANIES WITH MORE THAN ONE ANTIPSYCHOTICS IN CLINICAL TRIALS OR ON THE MARKET* 29
Chapter-4: TECHNOLOGY OVERVIEW
TECHNOLOGY OVERVIEW 30
TABLE 9 SALES OF ATYPICAL ANTIPSYCHOTICS BY FORMULATION, THROUGH 2014 ($, MILLIONS) 31
TABLE 10 ADMINISTRATION PROFILES OF LONG-ACTING ATYPICAL ANTIPSYCHOTICS 31
Chapter-5: PATENT EVALUATION
PATENT LENGTHS AND MARKET EXCLUSIVITY 32
TABLE 11 PATENT EXPIRATION DATES FOR ANTIPSYCHOTICS ON THE MARKET OR IN PHASE III DEVELOPMENT 33
TABLE 12 SALES OF ANTIPSYCHOTICS POTENTIALLY FACING GENERIC COMPETITION BY THE END OF 2014 ($ MILLIONS) 34
Chapter-6: ANTIPSYCHOTICS ON THE MARKET AND IN DEVELOPMENT
TABLE 13 GLOBAL MARKET FOR ANTIPSYCHOTICS BY INDIVIDUAL DRUG, THROUGH 2014 ($ MILLIONS) 35
TABLE 13 (CONTINUED) 36
TABLE 14 GLOBAL MARKET FOR ANTIPSYCHOTIC DRUGS BY MECHANISM OF ACTION, THROUGH 2014 ($ MILLIONS) 37
DOPAMINERGIC ANTIPSYCHOTICS IN DEVELOPMENT 37
DOPAMINE D2/SEROTONIN 5-HT2A RECEPTOR ANTAGONISTS 37
TABLE 15 MARKET FOR D2/5-HT2A ANTAGONISTS BY REGION, THROUGH 2014 ($ MILLIONS) 38
Serdolect (Sertindole) 38
Serdolect … (Continued) 39
Solian (Amisulpride) 40
Lonasen (Blonanserin) 40
Lullan (Perospirone) 41
Saphris/Sycrest (Asenapine, ORG 5222, SCH 900274) 41
Saphris/Sycrest (Continued) 42
Risperdal (Risperidone) 43
Risperdal Consta (Risperidone) 44
Risperdal Consta… (Continued) 45
Clozaril/Leponex (Clozapine) 46
Seroquel IR and XR (Quetiapine) 47
Seroquel IR and XR…(Continued) 48
Zyprexa (Olanzapine) 49
Zyprexa…(Continued) 50
Zyprexa Relprevv/Zypadhera (Olanzapine Pamoate) 51
Fanapt (Iloperidone) 51
Fanapt…(Continued) 52
AZ-004 (Staccato Loxapine) 53
TABLE 16 PROFILE OF AZ-004 VERSUS OTHER ANTIPSYCHOTICS FOR TREATING AGITATION 54
TABLE 17 AZ-004/STACCATO LOXAPINE STUDIES 55
Lurasidone (SM-13496) 56
TABLE 18 LURASIDONE STUDY RESULTS 57
Geodon/Zeldox (Ziprasidone) 58
Invega (Paliperidone) 59
TABLE 19 INVEGA COMPARED TO RISPERDAL 60
Invega Sustenna (Paliperidone Palmitate) 60
Zicronapine (Lu 31-130) 61
DOPAMINE D2 RECEPTOR PARTIAL AGONISTS 63
TABLE 20 MARKET FOR D2 PARTIAL AGONISTS BY REGION, THROUGH 2014 ($ MILLIONS) 64
Abilify (Aripiprazole, OPC-14597) 65
Aripiprazole Depot 66
Cariprazine (RGH-188, MP-214) 67
Cariprazine…(Continued) 68
ALKS 9070 (Long-acting Aripiprazole) 71
Bifeprunox (DU-127,090) 71
SEROTONERGIC ANTIPSYCHOTICS IN DEVELOPMENT 72
TABLE 21 SELECTED SEROTONIN RECEPTOR SUBTYPES AND ANTIPSYCHOTIC DRUGS BINDING TO THESE SITES 73
Pimavanserin (ACP-103) 74
Pimavanserin…(Continued) 75
TABLE 22 PIMAVANSERIN PHASE II ADJUNCTIVE SCHIZOPHRENIA EFFICACY RESULTS 76
5-HT6 RECEPTOR AGONISTS AND ANTAGONISTS 77
PF-5212365 (SAM-531) 78
Eplivanserin (SR46349B) 78
GLUTAMATERGIC ANTIPSYCHOTICS IN DEVELOPMENT 79
LY2140023 (Continued) 80
Glutamatergic Modulators in Preclinical Testing 82
GLYCINE TRANSPORT INHIBITORS 82
SCH 900435 (Org 25935) 82
OTHER ANTIPSYCHOTICS IN DEVELOPMENT 84
Talnetant (SB-223412) 87
Osanetant (SR-142801) 87
Licarbazepine (LIC477D) 88
Corlux (Mifepristone, RU-486, C-1073) 89
Corlux …(Continued) 90
SCH 900636 (ORG 34517) 91
Chapter-7: DISEASE APPLICATIONS
SYMPTOMS OF SCHIZOPHRENIA 94
TREATMENT OF SCHIZOPHRENIA 95
Treatment of Schizophrenia (Continued) 96
TESTS OF SCHIZOPHRENIA DRUG EFFECTIVENESS 97
Positive and Negative Syndrome Scale (PANSS) 97
Brief Psychiatric Rating Scale (BPRS) 97
Clinical Global Impression scale (CGI) 97
Scale for the Assessment of Positive Symptoms/Negative Symptoms (SAPS/SANS) 98
CATIE Phase 1 Results 99
TABLE 23 CATIE PHASE 1 ALL-CAUSE STUDY DISCONTINUATIONS 99
CATIE Phase 2 Results 100
CATIE Phase 3 Results 100
The Lancet Second-generation vs First-Generation Antipsychotics Meta-analysis 102
Young Mania Rating Scale 104
Montgomery-Asberg Depression Rating Scale 104
Hamilton Depression Rating Scale 104
MAJOR STUDIES USING ANTIPSYCHOTICS IN BIPOLAR DISORDER 105
MARKET OPPORTUNITY 106
TABLE 24 LIST OF APPROVED BIPOLAR I DISORDER USES FOR ATYPICAL ANTIPSYCHOTICS 107
MAJOR DEPRESSIVE DISORDER 108
MARKET OPPORTUNITY 109
OTHER ON- AND OFF-LABEL USES OF ANTIPSYCHOTICS 110
ANXIETY SPECTRUM DISORDERS 110
ALZHEIMER’S AND PARKINSON’S DISEASES 111
MARKET OPPORTUNITY 111
Market Opportunity (Continued) 112
Chapter-8: MAJOR COMPANIES AND MARKET SHARE
TABLE 25 FORECASTED SALES AND MARKET SHARE OF COMPANIES WITH ANTIPYSCHOTICS ON THE MARKET, 2014 ($ MILLIONS/%) 113
ACADIA PHARMACEUTICALS 114
ADDEX PHARMACEUTICALS 115
ALEXZA PHARMACEUTICALS 116
AstraZeneca – U.S. Headquarters 118
BRISTOL-MYERS SQUIBB 120
CYRENAIC PHARMACEUTICALS 121
DAINIPPON SUMITOMO PHARMA 122
FABRE-KRAMER PHARMACEUTICALS 123
JOHNSON AND JOHNSON 125
MITSUBISHI TANABE PHARMA 127
NPS PHARMACEUTICALS 130
OTSUKA PHARMACEUTICAL CO. 132
Pfizer (Continued) 133
TITAN PHARMACEUTICALS 134
VANDA PHARMACEUTICALS 135
Chapter-9: INTERNATIONAL ASPECTS AND REGULATORY ISSUES
TABLE 26 GLOBAL FORECAST FOR ANTIPSYCHOTICS MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 136
MARKET BY REGION (CONTINUED) 137
The FDA Modernization Act of 1997 138
Fast-track Status 139
Special Protocol Assessments 140
New Surveillance and Safety Requirements 140
Approvable Letters 140
Consumer Confidence 141
Other Health Care Changes 142
New Drug Approvals and Innovation 142
Drug Reimbursement and Reference Pricing 143
Relocation of R&D 144
New Drug Approvals 145
Regulatory Climate 145
Relationship Between Academia and Industry 146
Chapter-10: FUTURE DIRECTIONS
THE ROLE OF BIOMARKERS AND PHARMACOGENOMICS 147
COMBINATION THERAPIES 147
THE EFFECT OF GENERIC ANTIPSYCHOTICS ON PRICE 148
THE EFFECT OF GENERIC …(CONTINUED) 149
To order this report:
Drug and Medication Industry: Antipsychotic Drugs: Technologies and Global Markets
Drug and Medication Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Intl: +1 805-652-2626